Persistent global shortages of GLP-1 receptor agonists have forced major pharmaceutical manufacturers to allocate over $11 billion toward dedicated greenfield manufacturing sites. Contract development and manufacturing organizations report full capacity bookings through 2027.
Device Assembly Constraints
While active pharmaceutical ingredient synthesis has stabilized, the primary bottleneck has shifted to auto-injector pen assembly lines. Precision molding components and sterile fill-finish capacity remain severely constrained.
Impact on Biosimilar Competition
Supply imbalances are accelerating regulatory fast-track approvals for generic and biosimilar alternatives in developing markets. Patent holders are responding with defensive litigation and direct-to-consumer delivery models to preserve market share.